P

Pfizer

Biopharmaceutical company develops medicines and vaccines

Senior Computational Geneticist - Multiple Teams

Full-TimePosted on 8/12/2026Deadline 8/19/26
$106k - $176.6k/yr+ 15% bonus target + Share-based long-term incentive program
Senior
PhD
Cambridge, MA, USA
HybridHybrid role requiring on-site work an average of 2.5 days per week; relocation support may be available.
No H1B Sponsorship

About the job

Requirements
  • A PhD and post-doctoral experience in genetics, statistical genetics, or genetic epidemiology with two years of relevant experience are required.
  • Strong statistical and quantitative skills, including knowledge of epidemiological principles and population-based research, are required.
  • Experience managing large projects, collaborations, or consortia is required.
  • Demonstrated experience using generative artificial intelligence tools such as Microsoft Copilot, ChatGPT, Claude, or Gemini to support scientific research, knowledge synthesis, data interpretation, or analytical workflows is required.
  • Understanding of the capabilities, limitations, sources of bias, and appropriate application of large language models and other artificial intelligence technologies in biomedical research is required.
  • Ability to incorporate artificial intelligence-assisted approaches into scientific workflows while maintaining sound scientific judgment and critically evaluating results is required.
  • Experience analyzing genetic datasets and integrating additional data types to advance clinical and biological understanding is required.
  • Proficiency in programming, scripting, querying, or statistical analysis languages such as R, Python, Perl, or SQL is required.
  • Familiarity with genetics platforms is required.
  • Ability to interact and communicate effectively with multidisciplinary scientists, researchers, and non-scientists internally and externally is required.
  • Ability to perform complex statistical analysis is required.
Responsibilities
  • Provide quantitative genetics expertise and conduct analyses through interactions with biologists within the Internal Medicine Research Unit.
  • Apply genetics and functional genomics to identify novel therapeutic targets, review and validate therapeutic hypotheses, understand disease pathogenesis and causal pathways, identify mechanism-related biomarkers by integrating genetics with clinical and omics datasets, identify potential disease indications, and match novel therapies to patients with relevant disease subtypes.
  • Ensure high-quality genetic and omics data are incorporated into exploratory research by interacting with internal partners in statistics, bioinformatics, computational biology, clinical science, and project leadership.
  • Partner with artificial intelligence and machine learning scientists to identify opportunities where artificial intelligence-enabled approaches can enhance genetics-driven target discovery, causal inference, biological interpretation, biomarker identification, and patient stratification.
  • Collaborate with research biologists and project teams to translate genetic and related data into portfolio asset prioritization, and collaborate with clinical teams on patient selection, stratification, and trial design.
  • Evaluate and incorporate artificial intelligence-assisted approaches into genetics research workflows, including literature synthesis, knowledge discovery, biological interpretation, hypothesis generation, and integration of large-scale human genetics and multi-omics datasets.
  • Manage, develop, and maintain internal and external collaborative projects according to specified timelines and milestones.
  • Communicate study findings and analyses to internal partners, leadership, administration, and collaborators.
  • Manage, support, and promote relationships with the external community to add value to target selection and validation.
Desired Qualifications
  • Background in human biology or medicine, with knowledge of disease pathophysiology for metabolic disease.
  • Track record of innovative and impactful research in the genetics of complex traits, including peer-reviewed publications.
  • Experience applying large language models and artificial intelligence-enabled tools to scientific discovery, biological interpretation, literature review, knowledge extraction, or hypothesis generation.
  • Ability to identify opportunities where artificial intelligence can enhance scientific productivity and decision-making while recognizing when human expertise, experimental validation, or additional evidence is required.
  • Scientific leadership experience with responsibility for research project delivery.
  • Experience with at least one additional omics technology, such as metabolomics, lipidomics, transcriptomics, or epigenetics.
  • Ability to identify, propose, and develop new analytical concepts.
  • Ability to lead and support teams, multitask, prioritize competing time-sensitive projects, and work effectively in a multidisciplinary matrix research team.

About the company

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $15.0 billion, and management raised full-year guidance to $60.5-$62.5 billion.
  • FDA approved Pfizer's 2026-2027 XFG Comirnaty vaccine on August 28, 2026.
  • Innovent and Metsera expand Pfizer's pipeline, while non-COVID revenue grew 5% operationally in Q2.

What critics are saying

  • Eliquis loses protection by 2028, and Ibrance faces U.S. patent expiry in 2027.
  • Pfizer just cut MET-224o and PF-07976016, proving obesity execution remains fragile versus Lilly.
  • Sanofi, Arbutus, and Bayer lawsuits target mRNA and LNP royalties, while restructuring runs through 2029.

What makes Pfizer unique

  • Pfizer spans vaccines, oncology, and cardiometabolic drugs across 2026, unlike narrower peers.
  • Metsera gave Pfizer monthly GLP-1 and amylin assets, plus obesity scale overnight.
  • Its global manufacturing and distribution network keeps Comirnaty, Padcev, and Vyndaqel commercially resilient.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

↓ -3%

1 year growth

↓ -3%

2 year growth

↓ -3%
Yahoo Finance
Sep 24th, 2026
Bristol Myers Squibb vs Pfizer: which healthcare stock is a better buy in 2026?

Bristol Myers Squibb and Pfizer, two pharmaceutical giants facing patent cliffs on blockbuster drugs, are taking divergent approaches to growth. Bristol Myers focuses on oncology and immunology whilst Pfizer leverages pandemic-era cash for acquisitions in high-growth areas like obesity treatments. Bristol Myers reported FY 2025 revenue of $48.2 billion, down 0.2% year-over-year, with net income of $7.1 billion and a 14.6% net margin. The company maintains a debt-to-equity ratio of 2.6x and generated $12.8 billion in free cash flow. Pfizer's FY 2025 revenue totalled $62.6 billion, declining 1.6%, with net income of $7.8 billion and a 12.4% net margin. Recent acquisitions include Seagen and Metsera, positioning the firm in oncology and obesity markets. Both companies partner with distributors and maintain global operations across multiple therapeutic areas.

Yahoo Finance
Sep 23rd, 2026
Pfizer and Butterfly Network lead AI healthcare push with revenues up to $63.7B

Butterfly Network is commercialising AI-enhanced ultrasound devices designed to assist clinicians with real-time scan guidance. The company generates approximately $112 million in revenue from its handheld iQ devices and related software platforms, including Compass AI and ScanLab, with a market capitalisation of roughly $2.2 billion. In November 2025, Butterfly's subsidiary signed a five-year co-development and licensing agreement with Midjourney for exclusive access to its semiconductor-based ultrasound technology. The deal includes a $15 million upfront payment, $10 million in annual licence fees, and additional milestone-based payments. Pfizer, with $63.7 billion in recent revenue and a market value of $158.1 billion, is applying biomolecular AI foundation models to accelerate drug discovery and development across its Global Biopharmaceuticals Business segment. The company combines large-scale therapeutic operations with machine learning applications in molecule design, trial productivity, and manufacturing efficiency.

Yahoo Finance
Sep 20th, 2026
Pfizer CEO says major headwinds easing as drugmaker cuts $7.2B in costs, eyes oncology pipeline

Pfizer's chief executive Albert Bourla says the pharmaceutical company's major headwinds are easing. Speaking at a recent conference, Bourla identified three challenges facing the drugmaker in 2025: tariffs and drug pricing policies, declining coronavirus product sales, and patent cliffs. The company has addressed tariffs by signing agreements with the US government for reduced medicine prices in exchange for tariff breaks. Pfizer has exceeded Wall Street's earnings-per-share estimates in all 10 of its past quarterly reports, suggesting its coronavirus business no longer significantly impacts performance. However, major patent cliffs loom. Eliquis, which generated $4.6 billion in the first half of the year, could face generic competition by 2028. Cancer treatment Ibrance, with $2.1 billion in first-half revenue, faces US patent expiration in 2027. Pfizer has cut $7.2 billion in costs and expanded its pipeline through acquisitions and internal development, with new products generating $13 billion annually. The company offers a 6.2% dividend yield.

Yahoo Finance
Sep 10th, 2026
Medicus Pharma secures Pfizer ADC deal with $2M funding, advances SkinJect for rare cancer treatment

Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.

Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

INACTIVE